Related Experiment Video
Updated: Jun 16, 2026

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
Published on: October 20, 2023
Dopamine receptor agonists and sleep disturbances in Parkinson's disease
K Ray Chaudhuri1, Kartik Logishetty
1National Parkinson Foundation Centre of Excellence, King's College Hospital, University Hospital Lewisham, London, UK. ray.chaudhuri@uhl.nhs.uk
Abstract:
Non-ergot dopamine receptor agonists, such as ropinirole, pramipexole, rotigotine and apomorphine, may alleviate some non-motor symptoms in Parkinson's disease (PD) while others may be precipitated. In this review, we discuss how dopamine receptor agonists can both ameliorate and aggravate the sleep problems in PD, a key non-motor symptom of this disease.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview
Parkinson Disease ll: Pathophysiology
Parkinson Disease l: Introduction
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
REM Sleep Behavior Disorder
RBD is significantly associated with...

